Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database

Abstract

Background and purpose: Testosterone is an essential sex hormone in maintaining masculine characteristics, which is prescribed for male hypogonadism as testosterone replacement treatment (TRT). Herein, we investigated long-standing controversies about the association between TRT and major adverse cardiovascular events (MACEs), based on real world adverse event (AE) reports, registered in the Food and Drug Administration Adverse Event Reporting System (FAERS).Methods: Publicly available FAERS data from 1 January 2004 to 31 December 2022 were retrieved from the Food and Drug Administration (FDA) website. The data mining protocol including the reporting odds ratio (ROR) and the Bayesian confidence propagation neural network (BCPNN) was applied to analyze overreporting caused by risk factors and MACEs, including TRT, morbidities, and ages. The ROR and the BCPNN were also applied to investigate the annually developing trend of pharmacovigilance (PV) signals in the real world, retrospectively.Results: A total of 3,057 cases referring to MACEs, with a median age of 57 years old (yo), were identified from 28,921 cases of testosterone users. MACEs related to PV signals have emerged since 2014, including cardiac death, non-fatal myocardial infarction, and non-fatal stroke. Myocardial infarction (MI) (ROR: 9.46; IC025: 3.08), acute myocardial infarction (AMI) (ROR: 16.20; IC025: 3.72), ischemic cardiomyopathy (ROR: 11.63; IC025: 2.20), and cardiomyopathy (ROR: 5.98; IC025: 1.96) were the most significant signals generated, and weaker signals included cardiac failure acute (ROR: 4.01; IC025: 0.71), cardiac arrest (ROR: 1.88; IC025: 0.56), and ventricular fibrillation (VF) (ROR: 2.38; IC025: 0.38). The time-to-onset (TTO) of MACEs was calculated with a median of 246 days for AMI.Conclusion: For myocardial infarction and cardiomyopathy, TRT statistically tended to increase the risk of MACEs, while for cardiac arrhythmia, cardiac failure, and stroke, TRT demonstrated beneficial effects among the population with morbidities, such as testosterone deficiency (TD), diabetes mellitus (DM), and hypertension. MACEs were rare but led to serious outcomes including significant increase in death and disability. Since 2018, and before 2014, reports referring to TRT associated with MACEs were relatively scarce, which indicated that there might be a considerable number of cases that went unrecorded, due to neglection. Health workers and testosterone users might pay more attention to testosterone-induced MACEs.

Post-marketing risk analysis of bendamustine: a real-world approach based on the FAERS database

“…These analyses were conducted from the initial date of drug administration to the occurrence of specific AEs. We ensured the accuracy of our calculations by using only data that was fully reported with complete dates in the YYYYMMDD format, excluding cases with partial or missing dates ( Zhao et al, 2023 ). Additionally, we removed instances with input errors, such as those where the AE occurrence was reported to precede the start of drug administration.…”

The Use of Anabolic Steroids by Bodybuilders in the State of Sergipe, Brazil

“…Furthermore, the heart, as a central cardiac pump, triggers the systolic ejection of oxygen-rich blood into the arteries, leading to the perfusion of organs and tissues to maintain life, whether in physiological or altered conditions, such as during physical exercise, diabetes, and obesity [30][31][32][33]. Furthermore, hemodynamic homeostasis involves the precise regulation of blood pressure, coordinated by the autonomic nervous system and renal mechanisms, while blood composition is maintained by the processes of hematopoiesis and hormonal control [33][34][35][36].…”

Assessing the safety of bedaquiline: insight from adverse event reporting system analysis

“…It is a spontaneous reporting system that encompasses millions of drug adverse event (AE) reports, including all adverse event and medication use information ( Zou et al, 2023 ). It provides a vast source of real-world data for the early identification of AEs ( Zhao et al, 2023 ). AE information in the FAERS database is documented and analyzed individually, making the data more basic ( Wang J. et al, 2023 ).…”